Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

The FDA warns GLP-1 weight loss drug users of aspiration risks during anaesthesia Learn what this update means and how to ...

The U.S. Food and Drug Administration's recall concerns two butter products produced by Continental Dairy ...

The FDA added the warning to most of the drugs on Nov. 1, according to the agency’s website. The warning applies to GLP-1 ...

WASHINGTON, D.C. — Following scientific review by the U.S. Food and Drug Administration (FDA), the agency issued a renewal of ...

The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). ...

Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...

FDA's Human Foods Program released its 2025 Priority Deliverables today, which details the primary focuses for its first year under the reorganization. Highlights include a goal to issue guidance on ...

NeurAxis (NYSE:NRXS) announced today that the FDA granted an expanded 510(k) clearance for its IB-Stim non-implanted nerve ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA ... The first study was a two-part phase 1 trial in healthy adult ...